MicroRNAs in the Management of Heart Failure.
Cardiac fibrosis
cardiac remodeling
cardiomyocytes
cell therapy
inflammation
regeneration.
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
08
2020
revised:
13
01
2021
accepted:
14
01
2021
pubmed:
20
2
2021
medline:
28
8
2021
entrez:
19
2
2021
Statut:
ppublish
Résumé
In recent years much research has been devoted to the deployment of biomarkers in the field of heart failure. To study the potential of post-transcriptional regulation by microRNAs on the diagnosis, management and therapy of heart failure. Literature search focuses on the role of microRNAs in heart failure. MicroRNAs are expressed and regulated in the course of the pathological manifestations of heart failure (HF). This wide and uncharted area of genetic imprints consisting of small non-coding RNA molecule is upregulated and released into the bloodstream from organs under certain conditions and or stress. The use of genetically based strategies for the management of HF has gained great interest in the field of biomedical science because they can be used as biomarkers providing information regarding cardiac status and function. They also appear as promising tools with therapeutic potential because of their ability to induce changes at the cellular level without creating alterations in the gene sequence. In addition, with the advances in genomic sequencing, quantification and synthesis in technologies of microRNAs identification as well as the growing knowledge of the biology of miRNAs and their involvement in HF, it is expected to favorably affect the prognosis of HF patients. MicroRNAs are involved in the regulation of multibiological processes involved in the progress of heart failure. More studies are needed to achieve a clinical valuable implementation of microRNAs in the management of HF.
Sections du résumé
BACKGROUND
BACKGROUND
In recent years much research has been devoted to the deployment of biomarkers in the field of heart failure.
OBJECTIVES
OBJECTIVE
To study the potential of post-transcriptional regulation by microRNAs on the diagnosis, management and therapy of heart failure.
METHODS
METHODS
Literature search focuses on the role of microRNAs in heart failure.
RESULTS
RESULTS
MicroRNAs are expressed and regulated in the course of the pathological manifestations of heart failure (HF). This wide and uncharted area of genetic imprints consisting of small non-coding RNA molecule is upregulated and released into the bloodstream from organs under certain conditions and or stress. The use of genetically based strategies for the management of HF has gained great interest in the field of biomedical science because they can be used as biomarkers providing information regarding cardiac status and function. They also appear as promising tools with therapeutic potential because of their ability to induce changes at the cellular level without creating alterations in the gene sequence. In addition, with the advances in genomic sequencing, quantification and synthesis in technologies of microRNAs identification as well as the growing knowledge of the biology of miRNAs and their involvement in HF, it is expected to favorably affect the prognosis of HF patients.
CONCLUSION
CONCLUSIONS
MicroRNAs are involved in the regulation of multibiological processes involved in the progress of heart failure. More studies are needed to achieve a clinical valuable implementation of microRNAs in the management of HF.
Identifiants
pubmed: 33602070
pii: CMC-EPUB-114351
doi: 10.2174/0929867328666210218181441
doi:
Substances chimiques
Biomarkers
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4863-4876Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.